NL-OMON40849已完成不适用
Probing neuroprotective effects of single session rTMS on subsequent mood and emotional processing - rTMS effects on mood-induced biases
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •24 healthy, right-handed women using oral contraceptives and men (aged 18-35) with normal or corrected-to-normal vision
排除标准
- •* Epilepsy, convulsion or seizure (TMS)
- •* Serious head trauma or brain surgery
- •* Large or ferromagnetic metal parts in the head (except for a dental wire)
- •* Implanted cardiac pacemaker or neurostimulator
- •* Pregnancy
- •* History or current presence of any neurologic or psychiatric disease
- •* Any prescribed medication that can alter cortical excitability (e.g. antiepileptics, tricyclic anti-depressives or benzodiazepines) or can have an influence on the participant*s vigilance or cognitive performance within two weeks prior to participation
- •* Color blind
研究者
相似试验
进行中（未招募）
1 期
A randomised controlled trial of neuroprotection with lamotrigine in secondary progressive multiple sclerosis - Neuroprotection with lamotrigine in multiple sclerosisMultiple sclerosisEUCTR2005-001949-42-GBniversity College London120
招募中
2 期
europrotective Effects of Stingless Bee Honey (Trigona spp) Supplementation on Halting Vascular Mild Cognitive Impairment among Post-Stroke PatientsVascular Mild Cognitive Impairment among Post-Stroke PatientsStroke, Vascular Mild Cognitive ImpairmentTCTR20230320003niversiti Sains Malaysia90
进行中（未招募）
1 期
A research study looking at how safe somapacitan is and how well it works in children who need help to grow – REAL 9CTIS2022-501055-87-01ovo Nordisk A/S44
已完成
不适用
Assessing the neuro-protective effect of mild cooling in neonates receiving extra-corporeal membrane oxygenation (ECMO)ISRCTN72635512niversity Hospitals of Leicester NHS Trust (UK)118
已完成
2 期
Evaluation of the neuroprotector effect of an extract of stem bark of Mangifera indica L. (Vimang®) in patient with Spinocerebellar Hereditary Ataxia Type 2Spinocerebellar Hereditary Ataxia Type 2Spinocerebellar AtaxiasCerebellar AtaxiaAtaxiaSpinocerebellar DegenerationsCerebellar DiseasesHeredodegenerative Disorders, Nervous SystemNeurodegenerative DiseasesNervous System DiseasesSpinal Cord DiseasesDyskinesiasNeurologic ManifestationsGenetic Diseases, InbornBrain DiseasesRPCEC00000005Center of Pharmaceutical Chemistry20